This patient with BRCA2-mutated prostate cancer had a prolonged PSA response and improvement of bone metastases during 15 cycles (14 months of treatment) with ongoing PSA response when he discontinued his participation in the clinical trial and transitioned to olaparib. This evidence concerns the gene BRCA2 and prostate cancer.